(Press-News.org) Without a steady supply of blood, neurons can't work. That's why one of the culprits behind Alzheimer's disease is believed to be the persistent blood clots that often form in the brains of Alzheimer's patients, contributing to the condition's hallmark memory loss, confusion and cognitive decline.
New experiments in Sidney Strickland's Laboratory of Neurobiology and Genetics at Rockefeller University have identified a compound that might halt the progression of Alzheimer's by interfering with the role amyloid-β, a small protein that forms plaques in Alzheimer's brains, plays in the formation of blood clots. This work is highlighted in the July issue of Nature Reviews Drug Discovery.
For more than a decade, potential Alzheimer's drugs have targeted amyloid-β, but, in clinical trials, they have either failed to slow the progression of the disease or caused serious side effects. However, by targeting the protein's ability to bind to a clotting agent in blood, the work in the Strickland lab offers a promising new strategy, according to the highlight, which will be published in print on July 1.
This latest study builds on previous work in Strickland's lab showing amyloid-β can interact with fibrinogen, the clotting agent, to form difficult-to-break-down clots that alter blood flow, cause inflammation and choke neurons.
"Our experiments in test tubes and in mouse models of Alzheimer's showed the compound, known as RU-505, helped restore normal clotting and cerebral blood flow. But the big pay-off came with behavioral tests in which the Alzheimer's mice treated with RU-505 exhibited better memories than their untreated counterparts," Strickland says. "These results suggest we have found a new strategy with which to treat Alzheimer's disease."
RU-505 emerged from a pack of 93,716 candidates selected from libraries of compounds, the researchers write in the June issue of the Journal of Experimental Medicine. Hyung Jin Ahn, a research associate in the lab, examined these candidates with a specific goal in mind: Find one that interferes with the interaction between fibrinogen and amyloid-β. In a series of tests that began with a massive, automated screening effort at Rockefeller's High Throughput Resource Center, Ahn and colleagues winnowed the 93,000 contenders to five. Then, test tube experiments whittled the list down to one contender: RU-505, a small, synthetic compound. Because RU-505 binds to amyloid-β and only prevents abnormal blood clot formation, it does not interfere with normal clotting. It is also capable of passing through the blood-brain barrier.
"We tested RU-505 in mouse models of Alzheimer's disease that over-express amyloid- β and have a relatively early onset of disease. Because Alzheimer's disease is a long-term, progressive disease, these treatments lasted for three months," Ahn says. "Afterward, we found evidence of improvement both at the cellular and the behavioral levels."
The brains of the treated mice had less of the chronic and harmful inflammation associated with the disease, and blood flow in their brains was closer to normal than that of untreated Alzheimer's mice. The RU-505-treated mice also did better when placed in a maze. Mice naturally want to escape the maze, and are trained to recognize visual cues to find the exit quickly. Even after training, Alzheimer's mice have difficulty in exiting the maze. After these mice were treated with RU-505, they performed much better.
"While the behavior and the brains of the Alzheimer's mice did not fully recover, the three-month treatment with RU-505 prevents much of the decline associated with the disease," Strickland says.
The researchers have begun the next steps toward developing a human treatment. Refinements to the compound are being supported by the Robertson Therapeutic Development Fund and the Tri-Institutional Therapeutic Discovery Institute. As part of a goal to help bridge critical gaps in drug discovery, these initiatives support the early stages of drug development, as is being done with RU-505.
"At very high doses, RU-505 is toxic to mice and even at lower doses it caused some inflammation at the injection site, so we are hoping to find ways to reduce this toxicity, while also increasing RU-505's efficacy so smaller doses can accomplish similar results," Ahn says.
INFORMATION:
Potential Alzheimer's drug prevents abnormal blood clots in the brain
2014-06-27
ELSE PRESS RELEASES FROM THIS DATE:
'Bad' video game behavior increases players' moral sensitivity
2014-06-27
BUFFALO, N.Y. — New evidence suggests heinous behavior played out in a virtual environment can lead to players' increased sensitivity toward the moral codes they violated.
That is the surprising finding of a study led by Matthew Grizzard, PhD, assistant professor in the University at Buffalo Department of Communication, and co-authored by researchers at Michigan State University and the University of Texas, Austin.
"Rather than leading players to become less moral," Grizzard says, "this research suggests that violent video-game play may actually lead to increased moral ...
Ancient ocean currents may have changed pace and intensity of ice ages
2014-06-27
Climate scientists have long tried to explain why ice-age cycles became longer and more intense some 900,000 years ago, switching from 41,000-year cycles to 100,000-year cycles.
In a paper published this week in the journal Science, researchers report that the deep ocean currents that move heat around the globe stalled or may have stopped at that time, possibly due to expanding ice cover in the Northern Hemisphere.
"The research is a breakthrough in understanding a major change in the rhythm of Earth's climate, and shows that the ocean played a central role," says ...
Research gives unprecedented 3-D view of important brain receptor
2014-06-27
PORTLAND, Ore. — Researchers with Oregon Health & Science University's Vollum Institute have given science a new and unprecedented 3-D view of one of the most important receptors in the brain — a receptor that allows us to learn and remember, and whose dysfunction is involved in a wide range of neurological diseases and conditions, including Alzheimer's, Parkinson's, schizophrenia and depression.
The unprecedented view provided by the OHSU research, published online June 22 in the journal Nature, gives scientists new insight into how the receptor — called the NMDA receptor ...
Study: To address climate change, nothing substitutes for reducing CO2 emissions
2014-06-27
The politically expedient way to mitigate climate change is essentially no way at all, according to a comprehensive new study by University of Chicago climatologist Raymond Pierrehumbert.
Among the climate pollutants humans put into the atmosphere in significant quantities, the effects of carbon dioxide (CO2) are the longest-lived, with effects on climate that extend thousands of years after emissions cease. But finding the political consensus to act on reducing CO2 emissions has been nearly impossible. So there has been a movement to make up for that inaction by reducing ...
Some aggressive cancers may respond to anti-inflammatory drugs
2014-06-27
New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs used to treat rheumatoid arthritis.
Studying triple-negative breast cancer, researchers at Washington University School of Medicine in St. Louis found that some aggressive tumors rely on an antiviral pathway that appears to drive inflammation, widely recognized for roles in cancer, rheumatoid arthritis and other inflammatory diseases.
The tumors that activate this particular antiviral pathway always have dysfunctional forms of the proteins ...
Diamond plates create nanostructures through pressure, not chemistry
2014-06-27
ALBUQUERQUE, N.M. — You wouldn't think that mechanical force — the simple kind used to eject unruly patrons from bars, shoe a horse or emboss the raised numerals on credit cards — could process nanoparticles more subtly than the most advanced chemistry.
Yet, in a current paper in Nature Communications, Sandia National Laboratories researcher Hongyou Fan and colleagues appear to have achieved a start toward that end.
Their newly patented and original method uses simple pressure — a kind of high-tech embossing — to produce finer and cleaner results in forming silver ...
Research may yield new ways to treat antibiotic-resistant TB
2014-06-27
CORVALLIS, Ore. – Scientists in the United States and India have successfully modified the precursor to one of the drugs used to treat tuberculosis, an important first step toward new drugs that can transcend antibiotic resistance issues that experts consider a serious threat to global health.
The findings, reported in the Journal of Biological Chemistry, indicate that a new compound, 24-desmethylrifampicin, has much better antibacterial activity than rifampicin against multi-drug-resistant strains of the bacteria that cause tuberculosis.
Rifampicin and related drugs ...
Youth regularly receive pro-marijuana tweets
2014-06-27
AUDIO:
Twitter has become one of the most popular social media sites among young people, and researchers at Washington University School of Medicine in St. Louis have been looking at Twitter....
Click here for more information.
Hundreds of thousands of American youth are following marijuana-related Twitter accounts and getting pro-pot messages several times each day, researchers at Washington University School of Medicine in St. Louis have found.
The tweets are cause for ...
A new species of moth from the Appalachian Mountains named to honor the Cherokee Nation
2014-06-27
A small, drab and highly inconspicuous moth has been flitting nameless about its special niche among the middle elevations of one of the world's oldest mountain ranges, the southern Appalachian Mountains in North America. A team of American scientists has now identified this new to science species as Cherokeea attakullakulla and described it in a special issue of the open access journal ZooKeys.
In all probability, it has been frequenting these haunts for tens of millions of years before the first humans set foot on this continent, all the while not caring in the least ...
Kids who know unhealthy food logos more likely to be overweight
2014-06-27
The more a child is familiar with logos and other images from fast-food restaurants, sodas and not-so-healthy snack food brands, the more likely the child is to be overweight or obese.
And, unfortunately, studies have shown that people who are overweight at a young age, tend to stay that way.
A research team that included a Michigan State University professor tested kids on their knowledge of various brands – including their ability to identify items such as golden arches, silly rabbits and a king's crown – and found that those who could identify them the most tended ...